We know that HER2-positive breast cancer has the potential to behave more aggressively, and it has a higher risk of returning post-treatment. Historically, that was something that we could only lament ...

In late 2019, trastuzumab deruxtecan was approved for the treatment of metastatic HER2/neu-positive breast cancer based on a phase two single arm trial that showed an extremely high response rate ...

The percentages of HER-2 NEU positive patients in these years was 15.7%, 16.0%, and 9.4% in 2015, 2016 and 2017 respectively. This represented a 6.6% drop in HER-2 NEU positive patients from 2016 to ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

Of the 220 invasive cancers, 78 were node positive and 17 (22%) of these were HER-2/neu positive; 113 were node negative and 14 (12.5%) were HER-2/neu positive; in 29 cases axillary dissection was ...

Julie Fisher, MD, explains how she assesses HER2-positive breast cancer patients for treatment response, what side-effects can occur and how they can be managed. Julie Fisher, MD, ... Both pertuzumab ...

RESULTS: HER-2/neu status was available for 651 patients with ER-positive disease; 650, 608, and 353 patients were assessed by IHC, PCR, and FISH, respectively. Approximately one half received ...

In patients with MBC and HER2/neu overexpression or HER2 amplification, a combination of the humanized anti-HER2 monoclonal antibody trastuzumab and a taxane, with or without carboplatin, has been ...

HER2-positive breast cancer is different from other breast cancer types, so your treatment won’t necessarily be the same as someone else who has a different form of breast cancer.

T-DXd approved in metastatic HR-positive, HER2-low/ultralow disease following endocrine therapy. ... The FDA has specified use of the Ventana Pathway anti-HER2/neu (4B5) antibody assay.